Compare TLSA & LKSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLSA | LKSP |
|---|---|---|
| Founded | 2013 | 2024 |
| Country | United Kingdom | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.3M | 159.3M |
| IPO Year | 2017 | N/A |
| Metric | TLSA | LKSP |
|---|---|---|
| Price | $1.14 | $10.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 228.0K | 45.0K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $293.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $9.90 |
| 52 Week High | $2.60 | $10.15 |
| Indicator | TLSA | LKSP |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 57.91 |
| Support Level | $1.14 | $10.09 |
| Resistance Level | $1.44 | N/A |
| Average True Range (ATR) | 0.10 | 0.01 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 27.78 | 50.00 |
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Lake Superior Acquisition Corp is a blank check company.